콘텐츠로 건너뛰기
Merck
  • The acetazolamide challenge: techniques and applications in the evaluation of chronic cerebral ischemia.

The acetazolamide challenge: techniques and applications in the evaluation of chronic cerebral ischemia.

AJNR. American journal of neuroradiology (2009-02-28)
A S Vagal, J L Leach, M Fernandez-Ulloa, M Zuccarello
초록

The acetazolamide (ACZ) challenge test is a useful clinical tool and a reliable predictor of critically reduced perfusion. In patients with chronic steno-occlusive disease, the ability to maintain normal cerebral blood flow by reducing vascular resistance secondary to autoregulatory vasodilation is compromised. Identification of the presence and degree of autoregulatory vasodilation (reflecting the cerebrovascular reserve) is a significant prognostic factor in patients with chronic cerebrovascular disease. The pharmacologic challenge of a vasodilatory stimulus such as ACZ can also be used to optimize the treatment strategies for these patients. The pathophysiology, methods, and clinical applications of the ACZ challenge test are discussed in this article.

MATERIALS
제품 번호
브랜드
제품 설명

Acetazolamide for system suitability, European Pharmacopoeia (EP) Reference Standard
Acetazolamide, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Acetazolamide, ≥99%, powder
USP
Acetazolamide, United States Pharmacopeia (USP) Reference Standard